RecruitingPhase 3NCT06497465

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Johns Hopkins University
Principal Investigator
Ethel M Weld, MD
Johns Hopkins University
Intervention
Dolutegravir 50mg Tab(drug)
Enrollment
150 enrolled
Eligibility
15-99 years · All sexes
Timeline
20252029

Study locations (6)

Collaborators

ViiV Healthcare

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06497465 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials